1. Ahrenholz, D. H., and Simmons, R. L., 1980, Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli perionitis, Surgery 88:41–47.
2. Alberts, D. P., Agner, E., Silvestri, J. S., Kwon, C, Newlander, K., King, A. G., Pelus, L. M., DeMarsh, P. L., Frey, C., Petteway, S. R., Huffman, W. F., and Bhatnagar, P. K., 1993, Synthesis of a novel hematoregulatory peptide SK&F 107647, Am. Peptide Symp. 13:357–359.
3. Aviles, A., Guzman, R., Delgado, S., Nmabo, M. J., Gracia, E. L., and Diaz-Maqueo, J. C., 1996a, Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma, Am. J. Hematol. 52:275–280.
4. Aviles, A., Guzman, R., Gracia, E. L., Talavera, A., and Diaz-Maqueo, J. C., 1996b, Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia, Anticancer Drugs 7:392–397.
5. Babineau, T. J., Hackford, A., Kenler, A., Bistrian, B., Forse, R. A., Fairchild, P. G., Heard, S., Keroack, M., Caushaj, P., and Benotti, P., 1994, A phase II multicenter, double-blind, randomized, placebocontrolled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients, Arch. Surg. 129:1204–1210.